Response Pharmaceuticals has initiated subject enrolment for a Phase II trial of its drug candidate RDX-002, designed to manage weight rebound in patients ceasing treatment with Glucagon-like peptide 1 (GLP-1) agonists.
The drug candidate aims to reduce post-prandial triglyceride levels and improve cardiometabolic risk factors.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
RDX-002 is a potent, selective and gut-specific inhibitor of intestinal microsomal triglyceride transfer protein (iMTP).
By inhibiting iMTP, RDX-002 reduces the absorption of triglycerides and cholesterol post-meal, potentially aiding in weight management and cardiometabolic health. The drug is also being considered for patients on antipsychotic medication.
The double-blind study will assess the efficacy and tolerability of RDX-002 over a 12-week period.
Participants in the trial have previously experienced significant weight loss through GLP-1 agonist drugs but are now discontinuing their use. Data from the study is expected to be released in the second half of 2025.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataResponse Pharmaceuticals founder and CEO Eric Keller said: “In our initial studies in antipsychotic-induced weight gain (AIWG), RDX-002 has shown promise in counteracting weight gain associated with the use of common anti-psychotics with good initial tolerability.
“We are excited to evaluate its effect in this second and important weight management setting while we continue development for AIWG.”
Having undergone multiple Phase I and II clinical trials, RDX-002 has been administered to 496 healthy subjects and patients for up to 84 days.
The trials have shown promising results, with RDX-002 lowering post-prandial triglyceride and LDL cholesterol levels, as well as contributing to weight reduction.
Additionally, Response Pharmaceuticals will present findings from a proof-of-concept study of the drug at Obesity Week 2024, scheduled for 4 November 2024 in San Antonio.
In April this year, the company revealed that the Phase Ib clinical trial demonstrated positive results for RDX-002.
